|
Target Now
Caris MPI's first molecular profiling program, Target Now provides specific therapeutic options to cancer patients for whom all standard therapies have failed.
learn more...
PCA3 ProfileR
A urine-based assay used to provide physicians with information on patients who have an elevated serum PSA in conjunction with a previous negative prostate biopsy.
learn more...
Mammostrat
Mammostrat is a five-antibody prognostic test for estrogen receptor-expressing, hormone receptor-treated (tamoxifen) breast cancer patients with node-negative disease.
learn more...
CardioEvalutR
CardioEvaluatR is an advanced comprehensive cardiovascular testing program designed to help physicians and patients effectively track and address cardiovascular disease.
learn more...
Research & Development
Caris MPI is currently refining signature sets and is licensing the ability to launch tests.
learn more...
|
|
|
